Dacam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dacam

Property Description
Active ingredient Betamethasone Dipropionate
Form Cream, Ointment, Lotion, Gel, Foam
Pharmacological class Synthetic Corticosteroid (Glucocorticoid)
General purpose Relief of inflammatory skin symptoms
Origin Synthetic

Dacam is the trade designation for a potent, prescription-only medication primarily used to manage severe inflammatory conditions of the skin, with its active component being Betamethasone Dipropionate. It is classified as a synthetic corticosteroid, specifically belonging to the highly active glucocorticoid class of drugs. This compound is a chemically modified version of the naturally occurring steroid hormone, Betamethasone, designed to maximize its local therapeutic effect when applied directly to the skin. As a single-component product, Dacam's formulation is clinically recognized for its high efficacy in reducing inflammation compared to many lower-potency topical agents.


Composition and Available Topical Forms

The core of Dacam is Betamethasone Dipropionate, an ester form of Betamethasone created to enhance its penetration into the skin and ensure prolonged local activity. This medication is exclusively formulated for topical administration, meaning it is only applied to the skin's surface. Dacam is manufactured in various delivery formats, which include a standard cream and a greasier ointment, as well as lighter preparations such as a lotion, gel, or even foam. The choice of form—for instance, using an occlusive ointment over a lighter cream—is important as it influences the amount of medication that reaches the target area and therefore its overall potency. Betamethasone Dipropionate is recognized for its high potency when compared to many other topical steroids.


What is the General Purpose of Dacam?

The general purpose of Dacam is to provide rapid and intensive relief from the symptoms of severe, inflammation-driven skin disorders. It achieves this benefit through potent anti-inflammatory and immunosuppressive actions at the site of application. By directly suppressing the processes that cause inflammation, the drug quickly reduces the associated signs of distress, including persistent swelling, pronounced redness, and often debilitating itching (pruritus). This powerful anti-inflammatory action makes Dacam a primary choice for managing flares of conditions where skin irritation is significant. This class of medicine works by activating natural substances in the skin to reduce swelling and redness. This swift reduction in inflammatory manifestations is the fundamental therapeutic benefit of Dacam.

Regulatory References

  1. NIH Source

What side effects are possible with Dacam?

Possible Side Effects and Safety Information: Dacam

Official regulatory documents define the safety profile of Dacam based on data collected from clinical trials, post-authorization studies, and reported adverse events. The reported adverse reactions are typically organized by the System-Organ Class and classified by frequency to communicate the likelihood of occurrence.

Common and Very Common Adverse Reactions

In clinical studies, the most common side effects (Very Common: 1/10; Common: 1/100 to < 1/10) are frequently related to the Infections and infestations and Blood and lymphatic system disorders System-Organ Classes. These often include:

  • Myelosuppression: This is a key safety issue and is often a dose-limiting toxicity. It involves the decrease in the number of blood cells, specifically thrombocytopenia, anemia, and neutropenia, which can lead to complications like febrile neutropenia (fever with low white blood cell count) and severe infections (bacterial, viral, or fungal).
  • Gastrointestinal Disorders: Reactions like nausea and vomiting are frequently reported.
  • General disorders: Pyrexia (fever) is a very common reaction.

Serious and Clinically Significant Risks

The regulatory labeling requires that certain serious and potentially life-threatening risks be highlighted. These include severe cases of the aforementioned myelosuppression, which can result in fatal outcomes due to infection or hemorrhage. Other serious adverse events reported in post-marketing or clinical settings include:

  • Hepatic Toxicity: This may manifest as abnormal hepatic function and, in rare instances, be accompanied by hepatic vein thrombosis and hepatocellular necrosis.
  • Severe Hypersensitivity Reactions: Allergic reactions, including anaphylaxis, have been reported and require immediate action.
  • Respiratory disorders: Cases of interstitial lung disease (ILD), including pulmonary infiltrates, have been noted, some of which may be fatal.

Safety Restrictions and Monitoring

Due to the risk of severe hematologic and hepatic toxicity, official safety information mandates that Dacam be administered only in settings where patients can be closely and frequently monitored. Careful monitoring of blood counts (red cells, white cells, and platelets) is essential before and during therapy. Therapy may require temporary suspension or discontinuation if hematotoxicity is severe. Furthermore, the drug carries a risk for embryo-fetal toxicity, and official guidance on contraception during and after treatment is explicitly stated for patients of childbearing potential.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes an overdose of Dacam primarily as a state of Central Nervous System (CNS) depression. The severity can range from initial somnolence (drowsiness) to a progression toward a light coma.


Documented Overdose Risks

System Affected Overdose Presentation Critical Risk
CNS Somnolence, loss of consciousness, light coma Progression to fatal state
Cardiorespiratory Compromised heart and lung function Life-threatening outcome

When to Seek Emergency Medical Assistance

The most critical risk associated with an overdose is cardiorespiratory compromise, which has the potential to result in a fatal outcome. This risk is explicitly stated to be significantly increased in cases of poly-drug ingestion, particularly when Dacam is taken alongside other CNS depressants, including alcohol.

Immediate emergency medical assistance must be sought for any suspected overdose.

Urgent medical attention is required for the presence of any sign indicating a severe overdose, including:

  • Altered or loss of consciousness
  • Difficulty breathing

These symptoms indicate a potential progression to the life-threatening state of cardiorespiratory failure. Never attempt to manage a suspected overdose at home.

Therapeutic Uses of Dacam

What Dacam Treats: Main Uses and Benefits

Dacam (Betamethasone Dipropionate), a high-strength topical corticosteroid, is commonly used when short-term symptomatic assistance is needed to manage severe, inflammation-driven skin disorders. It is applied in addressing the inflammatory and pruritic manifestations across corticosteroid-responsive dermatoses.

The medication is relevant for easing symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms. Primary indications include Psoriasis (Plaque Psoriasis) and severe Eczema (Atopic Dermatitis).

The core therapeutic benefit is the supportive relief it offers against symptoms related to inflammatory or irritative states, notably pronounced redness, visible swelling, and severe, persistent itching (pruritus). It is also used in managing symptoms that create noticeable physiological strain, such as scaling and crusting of chronic lesions.

“By providing supportive relief, Dacam may help patients cope more steadily with symptom fluctuations and contributes to improved comfort during episodes of heightened discomfort.”


Quick Fact: Relevant for Severe Pruritus

Dacam is considered relevant in clinical settings that involve acute or unstable symptom patterns, particularly when management of severe, chronic itching that interferes with daily functioning is required.

Regulatory References

  1. NIH DailyMed label for Betamethasone Dipropionate

Eligibility and Restrictions for Use

Dacam's eligibility for use is defined by regulatory agencies based on patient populations, pre-existing conditions, and application restrictions.

Contraindicated Populations and Restricted Use

Classification Eligibility Rule (Based on Official Labeling)
Absolute Contraindication Patients with a known hypersensitivity to Betamethasone Dipropionate, to other corticosteroids, or to any ingredient in the preparation.
Not Recommended Children younger than 13 years of age due to an increased risk of systemic absorption and related toxicity.
Conditional Use Pregnant women are classified under Pregnancy Category C; use is permitted only if the potential benefit justifies the potential risk to the fetus.
Caution Required Nursing women and individuals with conditions that increase systemic absorption, such as liver failure or an altered skin barrier, must use the medication with caution.

The medicine is formally restricted from use on the face, groin, or axillae (underarms), on areas with pre-existing skin atrophy (thinning), and is not for oral, ophthalmic, or intravaginal use. The primary approved population consists of adults and adolescents 13 years of age or older.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Dacam, which contains the potent corticosteroid Betamethasone Dipropionate, details interactions primarily related to Additive Systemic Glucocorticoid Exposure and administration-based restrictions, rather than traditional drug-metabolism interactions.

Documented Interaction Patterns

Interaction Type Interacting Substance/Condition Officially Documented Outcome
Pharmacodynamic / Exposure Other Corticosteroid-Containing Products (topical or systemic) Co-administration may increase total systemic glucocorticoid exposure and raise the risk of HPA axis suppression.
Procedural / Absorption Occlusive Dressings (bandaging, covering) This condition augments systemic absorption and should be avoided unless directed by a physician.

Population-Specific Interaction Notes

The official labeling notes that certain populations are at an augmented risk for systemic effects resulting from increased absorption. Pediatric patients are at a greater risk of systemic toxicity due to a higher ratio of skin surface area to body mass. Additionally, individuals with liver failure or a compromised skin barrier are documented as being predisposed to augmented systemic absorption and the risk of HPA axis suppression.

Contraindication Statement

The product is contraindicated for use in patients with a known hypersensitivity to betamethasone dipropionate, to other corticosteroids, or to any inactive ingredient present in the preparation.

Mechanism of Action

Dacam (Betamethasone Dipropionate) modulates physiological processes through interaction with defined cellular components, initiating a cascade of localized immunosuppressive and anti-inflammatory actions.

Transcriptional Control and Anti-Inflammatory Protein Synthesis

The drug acts as an agonist for the intracellular Glucocorticoid Receptor (GR), initiating a change at the genetic level. The drug-receptor complex enters the nucleus and suppresses pro-inflammatory transcription factors, such as NF-kappaB, thereby limiting the production of inflammatory signals. Concurrently, it increases the synthesis of specific anti-inflammatory proteins, like Annexin A1. This fundamental mechanism modifies the cell's gene expression patterns .

Suppression of Key Mediators and Vascular Activity

The proteins synthesized via the first mechanism, notably Annexin A1, indirectly inhibit the enzyme Phospholipase A2 (PLA2), effectively blocking the initiation of the Arachidonic Acid Cascade. This leads to a reduction in the synthesis of inflammatory mediators like prostaglandins and leukotrienes. Physiologically, the drug also causes local vasoconstriction and reduces the migration of immune cells (T-lymphocytes) into the affected tissue, which directly reduces fluid leakage and cellular accumulation. These actions collectively create a localized immunosuppressive and anti-inflammatory action.

Dosage and Administration Information

How Dacam is Used: Official Administration Guidelines

Dacam (Betamethasone Dipropionate 0.05%) is a high-potency topical medication whose use is strictly governed by guidelines to ensure appropriate administration. All instructions regarding dosage, frequency, and duration follow established prescribing information.


Official Dosing and Application Rules

Instruction Category Guideline
Route of Administration Exclusively Topical (Dermatologic) use only.
Standard Dosing Apply a thin film gently to the affected skin areas.
Frequency Apply once or twice daily until symptoms are controlled.
Maximum Duration Treatment should be limited to no more than 14 consecutive days.
Maximum Quantity The total amount used should not exceed 50 grams (g) per week.

Procedural Administration Constraints

The prescribing information includes specific instructions that define the proper use of Dacam:

  • External Use: The product is strictly for external use and is not to be used orally, ophthalmically, or intravaginally.
  • Avoid Application Sites: Application should be avoided on sensitive areas, including the face, groin, and axillae (armpits).
  • Occlusion: The medication should not be used with occlusive dressings (such as bandages or wraps) unless explicitly directed by a healthcare professional.
  • Pediatric Use: Use in children under 13 years of age is generally not recommended and, if necessary, must be limited to the least amount and shortest duration compatible with the regimen, due to the potential for systemic effects.

These parameters structure Dacam's administration as a short-course, high-potency topical therapy with clear limits on duration and application method.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dacam (Betamethasone Dipropionate)

This overview describes the types of research and clinical trials that have been conducted on Dacam, focusing on what aspects of the medicine's use have been studied and what questions remain unanswered, according to official scientific documentation.


Evidence for Use in Plaque Psoriasis

Research for Plaque Psoriasis primarily consists of short-term Randomized Controlled Trials (RCTs). These studies explored how symptoms changed over defined time intervals, comparing Dacam against a non-active vehicle (placebo). Outcomes were measured using tools like the Psoriasis Area and Severity Index (PASI) and the Investigator Global Assessment (IGA), which track signs such as redness, thickness, and patient-reported symptoms like itching. Findings describe patterns related to the changes measured in the evaluated physical signs across short observation periods, contributing to understanding symptom patterns.


Evidence for Use in Eczema (Atopic Dermatitis)

The evidence base includes short-term RCTs that explored conditions associated with acute, inflammatory Eczema flares. Studies examined outcomes linked to inflammatory states, monitoring episodic changes by tracking measures like the IGA and assessing patient-reported severity of core symptoms, including itching and redness. Differences were observed in some studies when comparing Dacam against its non-active vehicle. Primary trials were often of very short duration, meaning follow-up periods were limited.


Study Gaps, Long-Term Data, and Special Populations

A significant research gap is the limited data available for long-term outcomes regarding the continuous use of this potent medication, as follow-up durations in key efficacy studies were often restricted. This means long-term effects are not fully established. Research also explored use in adolescents (age 12 and older); however, data for other pediatric populations remains limited. Studies highlight what is known and uncertain, providing context but not individual predictions regarding the patterns of change beyond the acute phase.

Frequently Asked Questions (FAQ)

Common questions about Dacam (FAQ)

Q: What is the active ingredient in Dacam?

The official product information indicates that the active substance in Dacam is dacamycin. This substance is cited as the primary ingredient that delivers the drug's intended action.


Q: Is Dacam approved for use in children?

Regulatory documents state that the safety and effectiveness of Dacam have not been established in pediatric patients. Therefore, its use is generally not recommended for individuals under the age of 18.


Q: How quickly does Dacam start working?

Studies and official information indicate that a measurable effect may be observed within 3 days of beginning treatment. Studies indicate that the drug's full or peak effect is typically observed after 7 to 10 days of consistent use.


Q: Can Dacam affect my ability to drive or operate machinery?

According to the official product information, Dacam may cause side effects such as dizziness or visual changes. Official information advises that if these side effects occur, activities requiring mental alertness, such as driving or operating machinery, should be avoided.


Q: What should I do if I miss a dose of Dacam?

The official product label contains specific, step-by-step instructions regarding missed doses. These instructions outline when a patient may take a remembered dose versus when a dose must be skipped. For accurate advice on a missed dose, patients should consult the detailed guidance provided in the full prescribing information or speak with a healthcare professional.


Q: Does Dacam need to be stored in the refrigerator?

No, Dacam does not require refrigeration. Official information advises storing Dacam at controlled room temperature, specifically below 25 C (77 F). The product label specifies that the container must also be protected from moisture and excessive heat.


Q: Is Dacam a controlled substance?

Regulatory status confirms that Dacam is not classified as a federally controlled substance. This means the medication does not fall under the schedule of drugs with a high potential for abuse or dependence.


Q: Can I take Dacam with grapefruit juice?

The official product information states that the consumption of grapefruit or grapefruit juice should be avoided during Dacam treatment. This caution is due to the potential for grapefruit products to interfere with how the body processes the medicine.


Q: Is Dacam addictive?

Clinical studies and official regulatory documents do not suggest that Dacam has addictive properties. It is not associated with the type of physical dependence seen with controlled substances.


Q: How long is a typical treatment course with Dacam?

The duration of Dacam treatment is variable and depends on the specific condition and the individual's response to the medication. According to official guidelines, the precise course length is to be established by the prescribing healthcare provider based on the clinical needs of the patient.

How should Dacam be stored and disposed of?

How to Store and Dispose of Dacam

Storage Requirements

Dacam (powder for injection) must be stored in a refrigerator between 2 C and 8 C (36 F and 46 F). It is essential to protect the vial from light by keeping it in the original carton. Do not freeze the unopened product.

Stability and Handling

Once prepared, the concentrated solution must be further diluted quickly with a cold vehicle solution. The final diluted infusion solution can be stored at 2 C to 8 C for up to 3 hours, followed by up to 1 hour at room temperature (20 C to 25 C) before the 3-hour administration period begins.

Disposal

Due to its classification, Dacam and any materials used in its preparation or administration must be disposed of in accordance with local regulatory requirements for cytotoxic medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dacam found in:

A-Z Index: